DIVA Laboratories Ltd (4153) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DIVA Laboratories Ltd (4153) has a cash flow conversion efficiency ratio of 0.005x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$5.57 Million ≈ $175.45K USD) by net assets (NT$1.03 Billion ≈ $32.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is DIVA Laboratories Ltd's balance sheet to measure how much of total assets are equity-financed.
DIVA Laboratories Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how DIVA Laboratories Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 4153 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
DIVA Laboratories Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DIVA Laboratories Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ktcs corporation
KO:058850
|
-0.054x |
|
Lowell Resources Fund
AU:LRT
|
0.028x |
|
Sempio Foods
KO:007540
|
0.024x |
|
Top Systems-L
TA:TOPS
|
0.143x |
|
News Network Corporation Public Company Limited
BK:NEWS
|
-0.007x |
|
Taiwan Ostor
TWO:8080
|
-0.864x |
|
Yonyu Plastics Co Ltd
TW:1323
|
0.013x |
|
Razor Labs Ltd
TA:RZR
|
2.512x |
Annual Cash Flow Conversion Efficiency for DIVA Laboratories Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of DIVA Laboratories Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see DIVA Laboratories Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.03 Billion ≈ $32.42 Million |
NT$20.77 Million ≈ $654.34K |
0.020x | -82.70% |
| 2024-12-31 | NT$1.06 Billion ≈ $33.25 Million |
NT$123.14 Million ≈ $3.88 Million |
0.117x | -52.36% |
| 2023-12-31 | NT$1.03 Billion ≈ $32.54 Million |
NT$252.91 Million ≈ $7.97 Million |
0.245x | +240.01% |
| 2022-12-31 | NT$1.02 Billion ≈ $32.02 Million |
NT$73.19 Million ≈ $2.31 Million |
0.072x | +723.74% |
| 2021-12-31 | NT$986.42 Million ≈ $31.08 Million |
NT$-11.39 Million ≈ $-358.85K |
-0.012x | +31.40% |
| 2020-12-31 | NT$988.89 Million ≈ $31.16 Million |
NT$-16.64 Million ≈ $-524.38K |
-0.017x | -136.22% |
| 2019-12-31 | NT$1.13 Billion ≈ $35.70 Million |
NT$52.66 Million ≈ $1.66 Million |
0.046x | -36.04% |
| 2018-12-31 | NT$1.18 Billion ≈ $37.30 Million |
NT$86.02 Million ≈ $2.71 Million |
0.073x | +41.41% |
| 2017-12-31 | NT$806.75 Million ≈ $25.42 Million |
NT$41.45 Million ≈ $1.31 Million |
0.051x | -- |
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the development, manufacture, and sale of medical equipment and computer related devices worldwide. The company provides endo/surgical displays, a static and dynamic image for hybrid and integrated ORs applications; color and mono displays for radiology and medical imaging applications; touch displays/human machine interface products; medical and industrial case… Read more